Advantages of incretin-based treatment in management of type 2 diabetes

摘要

The risk of hypoglycemia with sulfonylureas is higher in the presence of diabetic nephropathy. Selective DPP-4 inhibitors lead to physiologic increases in the incretins GLP-1 and gastric inhibitory polypeptide and preferable for the management of postprandial hyperglycemia due to lack of many adverse effects observed with other diabetes medications.